Cargando…

Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis

Spondyloarthritis Research Consortium Canada (SPARCC) score is an effective magnetic resonance imaging (MRI) evaluation method for inflammation in axial spondyloarthritis. Previously published meta-analyses have shown tumor necrosis factor α inhibitors (TNFi) had great effectiveness on improving dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yupeng, Chen, Yuehong, Liu, Tao, Lin, Sang, Yin, Geng, Xie, Qibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775088/
https://www.ncbi.nlm.nih.gov/pubmed/33382842
http://dx.doi.org/10.1371/journal.pone.0244788
_version_ 1783630400608796672
author Huang, Yupeng
Chen, Yuehong
Liu, Tao
Lin, Sang
Yin, Geng
Xie, Qibing
author_facet Huang, Yupeng
Chen, Yuehong
Liu, Tao
Lin, Sang
Yin, Geng
Xie, Qibing
author_sort Huang, Yupeng
collection PubMed
description Spondyloarthritis Research Consortium Canada (SPARCC) score is an effective magnetic resonance imaging (MRI) evaluation method for inflammation in axial spondyloarthritis. Previously published meta-analyses have shown tumor necrosis factor α inhibitors (TNFi) had great effectiveness on improving disease activity and function in axial spondyloarthritis. However, there still has no one that concentrates on the impact of TNFi on MRI inflammation. We conduct a meta-analysis to summarize the impact of TNFi on MRI inflammation in axial spondyloarthritis using SPARCC score. Comprehensive search was conducted in the databases of OVID Medline, OVID EMBASE, and Cochrane library on November 14, 2020. We investigated the differences in SPARCC score of sacroiliac joint and spine, before and after TNFi treatment in patients with axial spondyloarthritis. SPARCC score was further compared in the subgroup by diagnostic category and TNFi types. In addition, clinical assessment indicators including ankylosing spondylitis disease activity score, bath ankylosing spondylitis disease activity index, bath ankylosing spondylitis functional index, c-reactive protein were also analyzed. Data were pooled by mean differences (MD) with 95% confidence intervals (CI) and publication bias was assessed by Egger’s test. Jadad scale was applied to assess the quality of included trials. Compared with control group, TNFi significantly improved SPARCC score of sacroiliac joints (n = 11, MD = 2.86, 95% CI 2.50, 3.23) and spine (n = 5, MD = 1.87,95%CI 1.27, 2.46). This effect was consistent among subgroups by different diagnostic category (ankylosing spondylitis, non-radiographic axial spondyloarthritis) and TNFi types (adalimumab, certolizumab pegol). Analysis of clinical assessment indicators also confirmed the therapeutic effect on axial spondyloarthritis. Egger’s test suggested no possibility of publication bias. This meta-analysis shows that TNFi are effective to improve MRI inflammation in patients with axial spondyloarthritis and the treatment effectiveness is not affected by diagnostic category and TNFi types.
format Online
Article
Text
id pubmed-7775088
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77750882021-01-11 Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis Huang, Yupeng Chen, Yuehong Liu, Tao Lin, Sang Yin, Geng Xie, Qibing PLoS One Research Article Spondyloarthritis Research Consortium Canada (SPARCC) score is an effective magnetic resonance imaging (MRI) evaluation method for inflammation in axial spondyloarthritis. Previously published meta-analyses have shown tumor necrosis factor α inhibitors (TNFi) had great effectiveness on improving disease activity and function in axial spondyloarthritis. However, there still has no one that concentrates on the impact of TNFi on MRI inflammation. We conduct a meta-analysis to summarize the impact of TNFi on MRI inflammation in axial spondyloarthritis using SPARCC score. Comprehensive search was conducted in the databases of OVID Medline, OVID EMBASE, and Cochrane library on November 14, 2020. We investigated the differences in SPARCC score of sacroiliac joint and spine, before and after TNFi treatment in patients with axial spondyloarthritis. SPARCC score was further compared in the subgroup by diagnostic category and TNFi types. In addition, clinical assessment indicators including ankylosing spondylitis disease activity score, bath ankylosing spondylitis disease activity index, bath ankylosing spondylitis functional index, c-reactive protein were also analyzed. Data were pooled by mean differences (MD) with 95% confidence intervals (CI) and publication bias was assessed by Egger’s test. Jadad scale was applied to assess the quality of included trials. Compared with control group, TNFi significantly improved SPARCC score of sacroiliac joints (n = 11, MD = 2.86, 95% CI 2.50, 3.23) and spine (n = 5, MD = 1.87,95%CI 1.27, 2.46). This effect was consistent among subgroups by different diagnostic category (ankylosing spondylitis, non-radiographic axial spondyloarthritis) and TNFi types (adalimumab, certolizumab pegol). Analysis of clinical assessment indicators also confirmed the therapeutic effect on axial spondyloarthritis. Egger’s test suggested no possibility of publication bias. This meta-analysis shows that TNFi are effective to improve MRI inflammation in patients with axial spondyloarthritis and the treatment effectiveness is not affected by diagnostic category and TNFi types. Public Library of Science 2020-12-31 /pmc/articles/PMC7775088/ /pubmed/33382842 http://dx.doi.org/10.1371/journal.pone.0244788 Text en © 2020 Huang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Huang, Yupeng
Chen, Yuehong
Liu, Tao
Lin, Sang
Yin, Geng
Xie, Qibing
Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
title Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
title_full Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
title_fullStr Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
title_full_unstemmed Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
title_short Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A meta-analysis
title_sort impact of tumor necrosis factor α inhibitors on mri inflammation in axial spondyloarthritis assessed by spondyloarthritis research consortium canada score: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775088/
https://www.ncbi.nlm.nih.gov/pubmed/33382842
http://dx.doi.org/10.1371/journal.pone.0244788
work_keys_str_mv AT huangyupeng impactoftumornecrosisfactorainhibitorsonmriinflammationinaxialspondyloarthritisassessedbyspondyloarthritisresearchconsortiumcanadascoreametaanalysis
AT chenyuehong impactoftumornecrosisfactorainhibitorsonmriinflammationinaxialspondyloarthritisassessedbyspondyloarthritisresearchconsortiumcanadascoreametaanalysis
AT liutao impactoftumornecrosisfactorainhibitorsonmriinflammationinaxialspondyloarthritisassessedbyspondyloarthritisresearchconsortiumcanadascoreametaanalysis
AT linsang impactoftumornecrosisfactorainhibitorsonmriinflammationinaxialspondyloarthritisassessedbyspondyloarthritisresearchconsortiumcanadascoreametaanalysis
AT yingeng impactoftumornecrosisfactorainhibitorsonmriinflammationinaxialspondyloarthritisassessedbyspondyloarthritisresearchconsortiumcanadascoreametaanalysis
AT xieqibing impactoftumornecrosisfactorainhibitorsonmriinflammationinaxialspondyloarthritisassessedbyspondyloarthritisresearchconsortiumcanadascoreametaanalysis